{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:52:05Z","timestamp":1787939525187,"version":"build-2784847793"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40273-015-0288-5","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T08:36:46Z","timestamp":1431419806000},"page":"1029-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["A Systematic Review of the Economic and Humanistic Burden of Gout"],"prefix":"10.1007","volume":"33","author":[{"given":"Gemma E.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"288_CR1","unstructured":"National Health Service. NHS England advice on gout. 2014. http:\/\/www.nhs.uk\/conditions\/Gout\/Pages\/Introduction.aspx . Accessed 27 Aug 2014."},{"key":"288_CR2","unstructured":"University of Maryland. Gout. 2014. http:\/\/umm.edu\/health\/medical\/reports\/articles\/gout#ixzz3BzqKxW00 . Accessed 1 Sept 2014."},{"key":"288_CR3","unstructured":"National Health Service. NHS choices. Gout. 2014. http:\/\/www.nhs.uk\/Conditions\/Gout\/Pages\/Complications.aspx . Accessed 27 Aug 2014."},{"issue":"6","key":"288_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","volume":"12","author":"E Roddy","year":"2010","unstructured":"Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223.","journal-title":"Arthritis Res Ther."},{"issue":"5","key":"288_CR5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semnephrol.2011.08.004","volume":"31","author":"YH Rho","year":"2011","unstructured":"Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin Nephrol. 2011;31(5):410\u20139.","journal-title":"Semin Nephrol"},{"issue":"Suppl 1","key":"288_CR6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","volume":"8","author":"G Nuki","year":"2006","unstructured":"Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(Suppl 1):S1.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"288_CR7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","volume":"24","author":"EU Smith","year":"2010","unstructured":"Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24(6):811\u201327.","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"4","key":"288_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"5 Suppl","key":"288_CR9","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/RHU.0b013e3181896921","volume":"14","author":"LX Chen","year":"2008","unstructured":"Chen LX, Schumacher HR. Gout: an evidence-based review. J Clin Rheumatol. 2008;14(5 Suppl):S55\u201362.","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"288_CR10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"Suppl 5","key":"288_CR11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3949\/ccjm.75.Suppl_5.S9","volume":"75","author":"AL Weaver","year":"2008","unstructured":"Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008;75(Suppl 5):S9\u201312.","journal-title":"Cleve Clin J Med."},{"issue":"Suppl 2","key":"288_CR12","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","volume":"48","author":"M Doherty","year":"2009","unstructured":"Doherty M. New insights into the epidemiology of gout. Rheumatology. 2009;48(Suppl 2):ii2\u20138.","journal-title":"Rheumatology."},{"issue":"34\u201335","key":"288_CR13","first-page":"549","volume":"106","author":"AK Tausche","year":"2009","unstructured":"Tausche AK, Jansen TL, Schroder HE, Bornstein SR, Aringer M, Muller-Ladner U. Gout\u2013current diagnosis and treatment. Deutsches Arzteblatt Int. 2009;106(34\u201335):549\u201355.","journal-title":"Deutsches Arzteblatt Int."},{"issue":"8","key":"288_CR14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British society for rheumatology and british health professionals in rheumatology guideline for the management of gout. Rheumatology. 2007;46(8):1372\u20134.","journal-title":"Rheumatology"},{"issue":"10","key":"288_CR15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"key":"288_CR16","unstructured":"US Food and Drug Administration. FDA Approves Colchicine for Acute Gout, Mediterranean Fever. 2009. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm174620.htm . Accessed 8 Apr 2015."},{"issue":"10","key":"288_CR17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American college of rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"288_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87\u2013114.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"288_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47\u201356.","journal-title":"Am J Med."},{"issue":"1","key":"288_CR20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","volume":"44","author":"CG Jennings","year":"2014","unstructured":"Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014;44(1):25\u201330.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"288_CR21","first-page":"1575","volume":"31","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575\u201381.","journal-title":"J Rheumatol."},{"issue":"4","key":"288_CR22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/14656566.2015.997213","volume":"16","author":"PC Robinson","year":"2015","unstructured":"Robinson PC, Dalbeth N. Advances in pharmacotherapy for the treatment of gout. Expert Opin Pharmacother. 2015;16(4):533\u201346.","journal-title":"Expert Opin Pharmacother"},{"key":"288_CR23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-med-080911-105830","volume":"64","author":"DB Crittenden","year":"2013","unstructured":"Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med. 2013;64:325\u201337.","journal-title":"Annu Rev Med"},{"key":"288_CR24","unstructured":"European Medicines Agency. Krystexxa, pegloticase. 2013. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002208\/human_med_001591.jsp&mid=WC0b01ac058001d124 . Accessed 8 Apr 2015."},{"key":"288_CR25","unstructured":"US Food and Drug Administration. FDA approves new drug for gout. 2010. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm225810.htm . Accessed 8 Apr 2015."},{"key":"288_CR26","unstructured":"AstraZeneca. AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients. 2014. http:\/\/www.astrazeneca.com\/Media\/Press-releases\/Article\/13082014\u2013astrazeneca-announces-topline-results-from-the-phase . Accessed 8 Apr 2015."},{"key":"288_CR27","unstructured":"AstraZeneca. Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency. 2015. http:\/\/www.astrazeneca.com\/Media\/Press-releases\/Article\/20150122\u2013marketing-authorisation-application-for-gout . Accessed 8 Apr 2015."},{"issue":"2","key":"288_CR28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.rdc.2014.01.013","volume":"40","author":"NL Edwards","year":"2014","unstructured":"Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin N Am. 2014;40(2):375\u201387.","journal-title":"Rheum Dis Clin N Am"},{"key":"288_CR29","doi-asserted-by":"crossref","unstructured":"Drummond M, Sculpher M, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford University Press; 2005.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"issue":"4","key":"288_CR30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1017\/S0266462300012095","volume":"14","author":"P Jacobs","year":"1998","unstructured":"Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care. 1998;14(4):799\u2013808.","journal-title":"Int J Technol Assess Health Care."},{"key":"288_CR31","unstructured":"Organisation for Economic Co-operation and Development. PPPs and exchange rates. 2013. http:\/\/stats.oecd.org\/Index.aspx?DataSetCode=SNA_Table4# . Accessed 18 Dec 2014."},{"key":"288_CR32","unstructured":"Organisation for Economic Co-operation and Development. Consumer prices: consumer prices\u2014annual inflation. 2014. http:\/\/stats.oecd.org\/index.aspx?queryid=22519# . Accessed 18 Dec 2014."},{"issue":"7","key":"288_CR33","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med."},{"issue":"12","key":"288_CR34","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","volume":"26","author":"RA Brook","year":"2010","unstructured":"Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010;26(12):2813\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"288_CR35","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1185\/030079906X112606","volume":"22","author":"RA Brook","year":"2006","unstructured":"Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006;22(7):1381\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"288_CR36","first-page":"164","volume":"14","author":"EQ Wu","year":"2008","unstructured":"Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14(2):164\u201375.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"288_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","volume":"15","author":"R Halpern","year":"2009","unstructured":"Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"288_CR38","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1185\/03007990903017966","volume":"25","author":"R Halpern","year":"2009","unstructured":"Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"288_CR39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3899\/jrheum.080768","volume":"36","author":"JG Hanly","year":"2009","unstructured":"Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, et al. Gout in the elderly\u2013a population health study. J Rheumatol. 2009;36(4):822\u201330.","journal-title":"J Rheumatol."},{"issue":"5","key":"288_CR40","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.080487","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032\u201340.","journal-title":"J Rheumatol."},{"issue":"1","key":"288_CR41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","volume":"14","author":"NL Edwards","year":"2011","unstructured":"Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10\u20135.","journal-title":"J Med Econ."},{"issue":"3","key":"288_CR42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.clinthera.2012.01.020","volume":"34","author":"H Park","year":"2012","unstructured":"Park H, Rascati KL, Prasla K, McBayne T. Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther. 2012;34(3):640\u201352.","journal-title":"Clin Ther"},{"issue":"11","key":"288_CR43","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kes183","volume":"51","author":"JJ Saseen","year":"2012","unstructured":"Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology. 2012;51(11):2004\u201312.","journal-title":"Rheumatology"},{"issue":"6","key":"288_CR44","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/MJT.0b013e31820543c5","volume":"19","author":"EQ Wu","year":"2012","unstructured":"Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012;19(6):e157\u201366.","journal-title":"Am J Ther"},{"issue":"2","key":"288_CR45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/pop.2012.0057","volume":"16","author":"W Lynch","year":"2013","unstructured":"Lynch W, Chan W, Kleinman N, Andrews LM, Yadao AM. Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks. Popul Health Manag. 2013;16(2):138\u201345.","journal-title":"Popul Health Manag."},{"issue":"2","key":"288_CR46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.reuma.2012.06.014","volume":"9","author":"A Sicras-Mainar","year":"2013","unstructured":"Sicras-Mainar A, Navarro-Artieda R, Ibanez-Nolla J. Resource use and economic impact of patients with gout: a multicenter, population-wide study. Reumatol Clin. 2013;9(2):94\u2013100.","journal-title":"Reumatol Clin."},{"issue":"4","key":"288_CR47","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.21837","volume":"65","author":"R Garg","year":"2013","unstructured":"Garg R, Sayles HR, Yu F, Michaud K, Singh J, Saag KG, et al. Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res. 2013;65(4):571\u20137.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"288_CR48","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA Vera De","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res. 2014;66(10):1551\u20139.","journal-title":"Arthritis Care Res"},{"key":"288_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","volume":"75","author":"A Wertheimer","year":"2013","unstructured":"Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 2013;75:1\u20134.","journal-title":"Curr Ther Res Clin Exp."},{"issue":"11","key":"288_CR50","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","volume":"52","author":"P Chandratre","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology. 2013;52(11):2031\u201340.","journal-title":"Rheumatology"},{"issue":"10","key":"288_CR51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1742-1241.2006.01104.x","volume":"60","author":"HH Colwell","year":"2006","unstructured":"Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout assessment questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006;60(10):1210\u20137.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"288_CR52","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/rheumatology\/kem150","volume":"46","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. 2007;46(9):1441\u20134.","journal-title":"Rheumatology."},{"issue":"5","key":"288_CR53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/art.23575","volume":"59","author":"E Alvarez-Hernandez","year":"2008","unstructured":"Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, Teran-Estrada L, Bernard-Medina AG, Espinoza J, et al. Validation of the health assessment questionnaire disability index in patients with gout. Arthritis Rheum. 2008;59(5):665\u20139.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"288_CR54","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.080506","volume":"35","author":"JD Hirsch","year":"2008","unstructured":"Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, et al. Evaluation of an instrument assessing influence of gout on health-related quality of life. J Rheumatol. 2008;35(12):2406.","journal-title":"J Rheumatol."},{"issue":"5","key":"288_CR55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11136-008-9355-0","volume":"17","author":"D Khanna","year":"2008","unstructured":"Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of chronic gout. Qual Life Res. 2008;17(5):815\u201322.","journal-title":"Qual Life Res"},{"issue":"9","key":"288_CR56","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"JA Singh","year":"2008","unstructured":"Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"288_CR57","first-page":"620","volume":"26","author":"WJ Taylor","year":"2008","unstructured":"Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N. The health assessment questionnaire disability index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620\u20136.","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"288_CR58","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5):1041\u20138.","journal-title":"J Rheumatol."},{"issue":"5","key":"288_CR59","first-page":"582","volume":"48","author":"SJ Lee","year":"2009","unstructured":"Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology. 2009;48(5):582\u20136.","journal-title":"Rheumatology"},{"issue":"2010","key":"288_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S8310","volume":"1","author":"JD Hirsch","year":"2010","unstructured":"Hirsch JD, Terkeltaub R, Khanna D, Singh J, Sarkin A, Shieh M, et al. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010;1(2010):1\u20138.","journal-title":"Patient Relat Outcome Meas."},{"issue":"6","key":"288_CR61","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2753.2009.01303.x","volume":"16","author":"AJ Sarkin","year":"2010","unstructured":"Sarkin AJ, Levack AE, Shieh MM, Kavanaugh AF, Khanna D, Singh JA, et al. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract. 2010;16(6):1244\u20137.","journal-title":"J Eval Clin Pract."},{"issue":"9","key":"288_CR62","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s11136-010-9690-9","volume":"19","author":"MM Groen van","year":"2010","unstructured":"van Groen MM, ten Klooster PM, Taal E, van de Laar MA, Glas CA. Application of the health assessment questionnaire disability index to various rheumatic diseases. Qual Life Res. 2010;19(9):1255\u201363.","journal-title":"Qual Life Res"},{"issue":"11","key":"288_CR63","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/acr.20570","volume":"63","author":"N Dalbeth","year":"2011","unstructured":"Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res. 2011;63(11):1605\u201312.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"288_CR64","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/rheumatology\/ker023","volume":"50","author":"D Khanna","year":"2011","unstructured":"Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh AF, Terkeltaub RA, et al. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology. 2011;50(7):1331\u20136.","journal-title":"Rheumatology"},{"issue":"4","key":"288_CR65","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","volume":"50","author":"PP Khanna","year":"2011","unstructured":"Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740\u20135.","journal-title":"Rheumatology"},{"issue":"4","key":"288_CR66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/rheumatology\/keq387","volume":"50","author":"PM Klooster ten","year":"2011","unstructured":"ten Klooster PM, Oude Voshaar MA, Taal E, van de Laar MA. Comparison of measures of functional disability in patients with gout. Rheumatology. 2011;50(4):709\u201313.","journal-title":"Rheumatology"},{"issue":"6","key":"288_CR67","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/erp.12.60","volume":"12","author":"M DiBonaventura","year":"2012","unstructured":"DiBonaventura M, Andrews LM, Yadao AM, Kahler KH. The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension. Exp Rev Pharmacoecon Outcomes Res. 2012;12(6):821\u20139.","journal-title":"Exp Rev Pharmacoecon Outcomes Res."},{"key":"288_CR68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117.","journal-title":"Health Qual Life Outcomes."},{"issue":"8","key":"288_CR69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/RHU.0b013e3182779805","volume":"18","author":"WJ Taylor","year":"2012","unstructured":"Taylor WJ, House M, Horne A, McQueen FM, Dalbeth N. The work instability scale predicts absenteeism in people with gout and suggests a higher risk for those in manual occupations. J Clin Rheumatol. 2012;18(8):405\u201310.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"288_CR70","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/annrheumdis-2013-204344","volume":"73","author":"DG Hoy","year":"2014","unstructured":"Hoy DG, Smith E, Cross M, Sanchez-Riera L, Buchbinder R, Blyth FM, et al. The global burden of musculoskeletal conditions for 2010: an overview of methods. Ann Rheum Dis. 2014;73(6):982\u20139.","journal-title":"Ann Rheum Dis"},{"key":"288_CR71","first-page":"173","volume":"103","author":"GC Brown","year":"2005","unstructured":"Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc. 2005;103:173\u201386.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"5","key":"288_CR72","first-page":"453","volume":"15","author":"S Beard","year":"2014","unstructured":"Beard S, von Scheele B, Nuki G, Pearson I. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15(5):453\u201363.","journal-title":"Eur J Health Econ."},{"issue":"9","key":"288_CR73","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","volume":"161","author":"E Jutkowitz","year":"2014","unstructured":"Jutkowitz E, Choi HK, Pizzi LT, Kuntz KM. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014;161(9):617\u201326.","journal-title":"Ann Intern Med"},{"key":"288_CR74","doi-asserted-by":"crossref","unstructured":"Spaetgens B, Tran-Duy A, Wijnands JM, van der Linden S, Boonen A. Health and utilities in patients with gout under care of a rheumatologist: which factors contribute? Arthritis Care Res. 2015. doi: 10.1002\/acr.22551","DOI":"10.1002\/acr.22551"},{"issue":"2","key":"288_CR75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/COPD-57610","volume":"2","author":"AS Buist","year":"2005","unstructured":"Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, et al. the burden of obstructive lung disease initiative (BOLD): rationale and design. Copd. 2005;2(2):277\u201383.","journal-title":"Copd."},{"issue":"4","key":"288_CR76","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1183\/09031936.00108409","volume":"34","author":"M Rutten-van Molken","year":"2009","unstructured":"Rutten-van Molken M. Raising the awareness: projecting the future burden of COPD with the BOLD model. Eur Respir J. 2009;34(4):787\u20139.","journal-title":"Eur Respir J."},{"issue":"7","key":"288_CR77","first-page":"703","volume":"12","author":"AS Buist","year":"2008","unstructured":"Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis. 2008;12(7):703\u20138.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"7","key":"288_CR78","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s00125-002-0860-3","volume":"45","author":"M Massi-Benedetti","year":"2002","unstructured":"Massi-Benedetti M. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia. 2002;45(7):S1\u20134.","journal-title":"Diabetologia"},{"issue":"7","key":"288_CR79","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00125-002-0858-x","volume":"45","author":"B Jonsson","year":"2002","unstructured":"Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45(7):S5\u201312.","journal-title":"Diabetologia"},{"issue":"3","key":"288_CR80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hec.910","volume":"14","author":"A Bagust","year":"2005","unstructured":"Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217\u201330.","journal-title":"Health Econ"},{"issue":"5","key":"288_CR81","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361\u201378.","journal-title":"J Headache Pain."},{"issue":"7","key":"288_CR82","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1526-4610.2011.01945.x","volume":"51","author":"M Stokes","year":"2011","unstructured":"Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51(7):1058\u201377.","journal-title":"Headache."},{"issue":"10","key":"288_CR83","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0333102411410610","volume":"31","author":"KA Payne","year":"2011","unstructured":"Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, et al. The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia. 2011;31(10):1116\u201330.","journal-title":"Cephalalgia"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0288-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0288-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0288-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T22:57:44Z","timestamp":1717887464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0288-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0288-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}